Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
The firm has a $33 price target (~110% upside based on Sept. 18 close). Centessa has two orexin 2 receptor agonists in development: ORX750 in phase 1 for sleep-wake disorders -- with phase 2 expected to begin in Q4 -- and ORX142 in the preclinical stage for excessive daytime sleepiness. The company's lead candidate, in registrational phase, is SerpinPC, a subcutaneous biologic for hemophilia B. With the two sleep candidates derisked and with best-in-class potential, analyst Mayank Mamtani says that ORX750 could become a major player in the rare hypersomnia market currently valued at more than $5B. "We believe [total addressable market] expansion into broader neurodegenerative/psychiatric disorders, via follow-on molecule ORX142's progression through preclinical and IND-enabling studies, could further reset CNTA's valuation floor to levels seen in recent major pharma deals," Mamtani wrote, citing Bristol Myers Squibb ( BMY ) and AbbVie acquisitions of, respectively, Karuna The
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Crohn's Disease Therapeutics Pipeline Research Report 2024: Comprehensive Insights About 70+ Companies and 80+ Drugs [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Zeposia shows long-term efficacy [Seeking Alpha]Seeking Alpha
- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple SclerosisBusiness Wire
- Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 7/26/24 - Beat
BMY
Sec Filings
- 8/5/24 - Form 4
- 7/31/24 - Form 4
- 7/31/24 - Form 3/A
- BMY's page on the SEC website